Nucleic acid testing and tissue safety: An eye bankês five-year review of hiv and hepatitis testing for donor corneas

Ellen Heck, Allen Brown, H. Dwight Cavanagh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE:: Tissue safety and added testing is a frequent topic of discussion among those who must evaluate donor suitability and assure appropriate testing. Therefore, the purpose of this report was to examine the data of one eye bank (accredited by Eye Bank Association of America) for the presence or absence of reactive serology in 3592 donors over a 5-year period, from 2005 to 2010. METHODS:: The number of specific analytes, human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus, that were reactive and the number of multireactive serologies are presented along with reports related to the identification of nucleic acid testing (NAT), NAT-reactive donors in correlation with other antigen or antibody markers. Antigen or antibody markers are enzyme-linked immunosorbent assay immunoassay kit determinations. NATs are used to measure the presence of RNA or DNA virus. RESULTS:: The 249 donors with reactive serologies serve to confirm the importance of serologic testing in history-negative potential donors. Furthermore, the findings of 2 HIV NAT-only reactive individuals is significant because it may indicate an early unrecognized exposure and "window period" infectivity not recognized by antibody testing alone. These results support the appropriate inclusion of this added test to guarantee tissue safety. CONCLUSIONS:: The finding of 2 potential donors without identified risk factors but with reactive HIV NAT suggests the need for comprehensive serologic testing in conjunction with medical social history screening. Considered together, screening and testing offer the best allograft tissue safety currently available.

Original languageEnglish (US)
Pages (from-to)503-505
Number of pages3
JournalCornea
Volume32
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Eye Banks
Cornea
Nucleic Acids
Hepatitis
Serology
Safety
Antibodies
History
HIV
Antigens
HIV-2
DNA Viruses
RNA Viruses
Immunoassay
Hepatitis B virus
Hepacivirus
Allografts
Enzyme-Linked Immunosorbent Assay

Keywords

  • HIV window
  • nucleic acid
  • serology test

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Nucleic acid testing and tissue safety : An eye bankês five-year review of hiv and hepatitis testing for donor corneas. / Heck, Ellen; Brown, Allen; Cavanagh, H. Dwight.

In: Cornea, Vol. 32, No. 4, 04.2013, p. 503-505.

Research output: Contribution to journalArticle

@article{7d91b53f48084824a62ffae0c2cef2e7,
title = "Nucleic acid testing and tissue safety: An eye bank{\^e}s five-year review of hiv and hepatitis testing for donor corneas",
abstract = "PURPOSE:: Tissue safety and added testing is a frequent topic of discussion among those who must evaluate donor suitability and assure appropriate testing. Therefore, the purpose of this report was to examine the data of one eye bank (accredited by Eye Bank Association of America) for the presence or absence of reactive serology in 3592 donors over a 5-year period, from 2005 to 2010. METHODS:: The number of specific analytes, human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus, that were reactive and the number of multireactive serologies are presented along with reports related to the identification of nucleic acid testing (NAT), NAT-reactive donors in correlation with other antigen or antibody markers. Antigen or antibody markers are enzyme-linked immunosorbent assay immunoassay kit determinations. NATs are used to measure the presence of RNA or DNA virus. RESULTS:: The 249 donors with reactive serologies serve to confirm the importance of serologic testing in history-negative potential donors. Furthermore, the findings of 2 HIV NAT-only reactive individuals is significant because it may indicate an early unrecognized exposure and {"}window period{"} infectivity not recognized by antibody testing alone. These results support the appropriate inclusion of this added test to guarantee tissue safety. CONCLUSIONS:: The finding of 2 potential donors without identified risk factors but with reactive HIV NAT suggests the need for comprehensive serologic testing in conjunction with medical social history screening. Considered together, screening and testing offer the best allograft tissue safety currently available.",
keywords = "HIV window, nucleic acid, serology test",
author = "Ellen Heck and Allen Brown and Cavanagh, {H. Dwight}",
year = "2013",
month = "4",
doi = "10.1097/ICO.0b013e3182653a7a",
language = "English (US)",
volume = "32",
pages = "503--505",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Nucleic acid testing and tissue safety

T2 - An eye bankês five-year review of hiv and hepatitis testing for donor corneas

AU - Heck, Ellen

AU - Brown, Allen

AU - Cavanagh, H. Dwight

PY - 2013/4

Y1 - 2013/4

N2 - PURPOSE:: Tissue safety and added testing is a frequent topic of discussion among those who must evaluate donor suitability and assure appropriate testing. Therefore, the purpose of this report was to examine the data of one eye bank (accredited by Eye Bank Association of America) for the presence or absence of reactive serology in 3592 donors over a 5-year period, from 2005 to 2010. METHODS:: The number of specific analytes, human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus, that were reactive and the number of multireactive serologies are presented along with reports related to the identification of nucleic acid testing (NAT), NAT-reactive donors in correlation with other antigen or antibody markers. Antigen or antibody markers are enzyme-linked immunosorbent assay immunoassay kit determinations. NATs are used to measure the presence of RNA or DNA virus. RESULTS:: The 249 donors with reactive serologies serve to confirm the importance of serologic testing in history-negative potential donors. Furthermore, the findings of 2 HIV NAT-only reactive individuals is significant because it may indicate an early unrecognized exposure and "window period" infectivity not recognized by antibody testing alone. These results support the appropriate inclusion of this added test to guarantee tissue safety. CONCLUSIONS:: The finding of 2 potential donors without identified risk factors but with reactive HIV NAT suggests the need for comprehensive serologic testing in conjunction with medical social history screening. Considered together, screening and testing offer the best allograft tissue safety currently available.

AB - PURPOSE:: Tissue safety and added testing is a frequent topic of discussion among those who must evaluate donor suitability and assure appropriate testing. Therefore, the purpose of this report was to examine the data of one eye bank (accredited by Eye Bank Association of America) for the presence or absence of reactive serology in 3592 donors over a 5-year period, from 2005 to 2010. METHODS:: The number of specific analytes, human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus, that were reactive and the number of multireactive serologies are presented along with reports related to the identification of nucleic acid testing (NAT), NAT-reactive donors in correlation with other antigen or antibody markers. Antigen or antibody markers are enzyme-linked immunosorbent assay immunoassay kit determinations. NATs are used to measure the presence of RNA or DNA virus. RESULTS:: The 249 donors with reactive serologies serve to confirm the importance of serologic testing in history-negative potential donors. Furthermore, the findings of 2 HIV NAT-only reactive individuals is significant because it may indicate an early unrecognized exposure and "window period" infectivity not recognized by antibody testing alone. These results support the appropriate inclusion of this added test to guarantee tissue safety. CONCLUSIONS:: The finding of 2 potential donors without identified risk factors but with reactive HIV NAT suggests the need for comprehensive serologic testing in conjunction with medical social history screening. Considered together, screening and testing offer the best allograft tissue safety currently available.

KW - HIV window

KW - nucleic acid

KW - serology test

UR - http://www.scopus.com/inward/record.url?scp=84875228245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875228245&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3182653a7a

DO - 10.1097/ICO.0b013e3182653a7a

M3 - Article

C2 - 23023406

AN - SCOPUS:84875228245

VL - 32

SP - 503

EP - 505

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 4

ER -